There is minimally a
UPSIDE/DOWNSIDE8.5% Upside
$76.22 Price Target
"Viking Therapeutics (VKTX) has emerged as a potential takeover target due to its promising weight-loss drug data, particularly the positive results from its Phase 2 trial for the VK2735 weight-loss drug. Analysts have raised their price targets for Viking Therapeutics, with Maxim analysts setting a target of $120 and Raymond James analysts raising theirs to $115. The company's stock has seen significant gains, up 392% year-to-date. Viking's attractiveness as an acquisition target is further enhanced by its NASH program for nonalcoholic steatohepatitis treatment and its potential in the weight loss drug market"
No comments:
Post a Comment